yes I know it doesn't exist, the point was to try and make one. people can ask similar questions and get this level of detail as an answer
""LR3 IGF-I is not well understood. Various considerations apply to its practical use for muscle growth. These include the fact that its resistance to binding IGFBP-3 renders it less potent vs. IGF-1 (rhIGF-I; mecasermin; Increlex) per-mcg when used systemically & by extension, less potent vs. GH (rhGH) under the same conditions (rhGH > rhIGF-I > LR3 IGF-I in potency to increase total body & muscle size [mitogenic & myogenic effects]).
For example, where a 2 IU/m² (BSA) rhGH dose, or 3.8 IU/d for a 75 kg, 5'9" (175.25 cm) man, serum IGF-I ↑ from 162→439 μg/L (high-normal). An 80 μg/kg (6 mg/d for that same average build man) serum IGF-I ↑ 156→342 μg/L. LR3, then, used systemically by a bodybuilder (characterized by high body surface areas & body weights) probably requires doses above 6 mg/d for equivalent potency to rhIGF-I – however, note that LR3 IGF-I will more likely reduce serum IGF-I because it is an IGF-I analogue designed specifically for rapid clearance & resistance to IGFBP binding.
If you are wondering how rhGH can be superior to rhIGF-I in increasing IGF-I, it is because GH in healthy individuals potently stimulates its synthesis & secretion. RhIGF-I is approved for one rare condition: Severe Primary IGF-I Deficiency (Primary IGFD). Having this condition means that your liver is resistant to GH stimulation of IGF-I. It is, then, a workaround option, to directly administer IGF-I despite its inferiority if otherwise non-primary-IGFD. Its financial expense arises because of market forces, supply & demand, and probably R&D, manufacturing, and transport/supply chain factors.
If LR3 IGF-I is to be used, it should be while bulking (energy in > out) on a per-muscle (not muscle group) rotational basis since it is less potent systemically (due to resistance to IGFBP-3 binding) than rhIGF-I & rhGH.
Split dosing (e.g., 2X/d > 1X/d; b.i.d.; b.d.s.) is superior to once-daily dosing (q.d.) because of the rapid clearance and low biological half-life of LR3 IGF-I that is particularly resistant to IGFBP binding.
LR3 IGF-I is more potent than any other known agent in its propensity to increase gut/visceral organ growth.
LR3 IGF-I's use is limited to a very particular use case – to increase the pool of available myofibers for subsequent hypertrophy in those very muscular bodybuilders that have already reached the limit of their pool (mitogenic vs. myogenic effects). Its propensity to induce hypoglycemia attaches with similar considerations to insulin (rhI) use.
The financial expense and relatively weak potency of LR3 to directly stimulate muscle growth (and very poor performance in anticatabolism, to stave off muscle losses during dieting) limit its versatility tremendously and make it an unlikely choice for the average reader. This one is really for the very advanced bodybuilder.""
since there are people who clearly know what they are talking about.
anyone want to take a shot at dosing levels/methods?